Catalent Finishes First Batch of Flu Vax

Catalent Pharma Solutions, has completed the first influenza vaccine manufacturing campaign at its new prefilled syringe manufacturing facility in Neder-Over-Heembeek, Belgium.

The production campaign exceeded 21 million prefilled syringes for the 2007 campaign. The facility replaces existing operations in Brussels. Catalent received initial European regulatory approval for this facility in July 2006, and expects to have the first FDA product approved at the facility in 2008.

“We are pleased to be able to partner with our customers for products with such far-reaching public health benefit,” said Richard Yarwood, the Group President of Catalent’s Sterile Technologies segment. “Our new facility gives us substantial additional capacity to serve the high-demand prefilled syringe market globally.”